Orkambi (lumacaftor/ivacaftor)
Status:
Negotiations were not pursued
Manufacturer:
Vertex Pharmaceuticals (Canada) Incorporated
Indication:
Cystic Fibrosis, F508del CFTR mutation
Last updated February 19, 2019
Juluca (dolutegravir/rilpivirine)
Status:
Concluded with an LOI
Manufacturer:
ViiV Healthcare
Indication:
HIV-1 Infection
Last updated February 13, 2019
Status:
Concluded with an LOI
Manufacturer:
Hoffmann-La Roche Ltd.
Indication:
Primary Progressive Multiple Sclerosis
Last updated February 13, 2019
Status:
Concluded with an LOI
Manufacturer:
Hoffmann-La Roche Ltd.
Indication:
Multiple Sclerosis, Relapsing
Last updated February 13, 2019
Besponsa (inotuzumab ozogamicin)
Status:
Concluded with an LOI
Manufacturer:
Pfizer Canada ULC
Indication:
Acute Lymphoblastic Leukemia (ALL)
Last updated February 6, 2019
Status:
Concluded with an LOI
Manufacturer:
Servier Canada Inc.
Indication:
Venous thromboembolism, treatment and recurrence prevention
Last updated February 5, 2019
Status:
Concluded with an LOI
Manufacturer:
Servier Canada Inc.
Indication:
Non-valvular atrial fibrillation, prevention of stroke and systemic embolism
Last updated February 5, 2019
Status:
Negotiations were not pursued
Manufacturer:
Eisai Limited
Indication:
Advanced or Metastatic Clear-cell Renal Cell Carcinoma
Last updated January 31, 2019
Status:
Concluded without agreement
Manufacturer:
Eli Lilly Canada Inc.
Indication:
Advanced Soft Tissue Sarcoma
Last updated January 31, 2019
Status:
Concluded without agreement
Manufacturer:
Novo Nordisk Canada Inc.
Indication:
Diabetes Mellitus, Type 1 & 2
Last updated January 30, 2019